Stem Cell Therapy for T1 D and T2 D Diabetic patients

2020 ◽  
Vol 11 (10) ◽  
pp. 23-25
Author(s):  
Nandakumar Ravichandran
Keyword(s):  
Diabetic Retinopathy ◽  
Beta Cells ◽  
Chronic Condition ◽  
Major Complication ◽  
Limb Ischemia ◽  
Diabetic Patients ◽  
Insulin Production ◽  
Working Age

Diabetes is a chronic condition that causes several diseases. Type 1 and Type 2 dependent diabetes are shown more concern in today’s world. Type1 dependent patients suffers from inability of the Beta cells to produce insulin whereas Type 2 dependent patients suffers from insufficient insulin production. Diabetic Retinopathy, Nephropathy, Critical Limb Ischemia and impaired glucose tolerance are some of the major risk factors of Diabetes. Diabetic Retinopathy is a major complication of Diabetes causing blindness in working age adults. This article discusses some research methods involved in the generation of Beta cells carried out by certain authors, hypothesis and future works in this field.

scholarly journals DIABETIC RETINOPATHY;

2019 ◽  
Vol 26 (04) ◽  
Author(s):  
Jamal ud Din ◽  
Zahidullah Khan ◽  
Inamullah Khan
Keyword(s):  
Diabetic Retinopathy ◽  
Age Distribution ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Study Population ◽  
Prime Objective ◽  
One Year ◽  
Fundoscopic Examination

Objectives: The prime objective of the study was to determine the prevalence of Diabetic Retinopathy in recently diagnosed type 2 diabetic patients with duration up to one year. Study Design: Single center, descriptive, observational study. Setting: Department of Medicine, Khyber Teaching Hospital, Peshawar. Period:  August, 2017 to March, 2018. Material and Methods: A total of 196 patients who were either newly diagnosed or diagnosed within last 12 months were included in the study. Patients with type 1 diabetes or diagnosed later than 12 months were excluded from the study. Patients with retinopathy due to some other cause were also excluded from the study. Both out door patients and admitted patients were included in the study. After detailed history, proper fundoscopic examination of both eyes was performed and findings were recorded on preformed proforma. Results: A total of 196 patients were enrolled in the study. One hundred and ten were male and 86 were female in a ratio of 1.3:1 respectively. Age distribution amongst study population ranged between 30-60 years. Mean age of the population was 49.18 ± 7.62 SD years with median age 48 years and mode age 45 years. Out of 196 patients, 32 (16.3%) patients had diabetic retinopathy on proper fundoscopic examination. Conclusion: Diabetic retinopathy is a well known microvascular complication of diabetes mellitus and any one with this complication must be referred to specialist ophthalmologist for further necessary investigation and management to prevent further complications.

Complications of Diabetes Mellitus

2010 ◽  
Author(s):  
Samuel Dagogo-Jack
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Diabetic Retinopathy ◽  
Diabetic Complications ◽  
Diabetic Patients ◽  
Complications Of Diabetes ◽  
Risk Of Death

The long-term complications of diabetes mellitus include retinopathy, nephropathy, and neuropathy. Diabetic retinopathy can result in loss of vision; nephropathy may lead to end-stage kidney disease (ESKD); and neuropathy poses the risk of foot ulcers, amputation, Charcot joints, sexual dysfunction, and potentially disabling dysfunction of the stomach, bowel, and bladder. Hyperglycemia sufficient to cause pathologic and functional changes in target tissues may be present for some time before clinical symptoms lead to a diagnosis of diabetes, especially in patients with type 2 diabetes. Diabetic patients are also at increased risk for atherosclerotic cardiovascular, peripheral vascular, and cerebrovascular disease. These conditions may be related to hyperglycemia, as well as to the hypertension and abnormal lipoprotein profiles that are often found in diabetic patients. Prevention of these complications is a major goal of current therapeutic policy and recommendations for all but transient forms of diabetes. This chapter describes the pathogenesis, screening, prevention, and treatment of diabetic complications, as well as the management of hyperglycemia in the hospitalized patient. Figures illustrate the pathways that link high blood glucose levels to microvascular and macrovascular complications; fundus abnormalities in diabetic retinopathy; the natural history of nephropathy in type 1 diabetes; cumulative incidence of first cardiovascular events, stroke, or death from cardiovascular disease in patients with type 1 diabetes; the effect of intensive glycemic therapy on the risk of myocardial infarction, major cardiovascular event, or cardiovascular death in patients with type 2 diabetes; and risk of death in patients with type 2 diabetes who receive intensive therapy of multiple risk factors or conventional therapy. Tables describe screening schedules for diabetic complications in adults, foot care recommendations for patients with diabetes, and comparison of major trials of intensive glucose control. This chapter has 238 references.

scholarly journals The role of microparticles in pathomechanisms of diabetic retinopathy – analysis of intercellular communication mechanisms in endothelial aging. Case control study in patients with metabolic syndrome, diabetes type 1 and type 2

2014 ◽  
Vol 83 (4) ◽  
pp. 322-327
Author(s):  
Ewa Stępień ◽  
Iwona Szuścik ◽  
Aleksandra Tokarz ◽  
Francisco J. Enguita ◽  
Bogdan Solnica ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Diabetic Retinopathy ◽  
Diabetic Patients ◽  
Imaging Method ◽  
Membrane Glycoproteins

The project is proposed to explain the role of specific circulating microparticles (MPs) as conveyors in trafficking bio-active molecules in type 1 (T1DM) and type 2 (T2DM) diabetic patients with risk of diabetic retinopathy (DR) and in patients with metabolic syndrome (MS). The possible role of miRNAs as modulators of these processes (in switching on/off mechanism on the molecular level) is proposed. An increased number of MPs with respect to glucose concentrations and levels of proangiogenic factors in vivo (patients’ plasma) is expected. The relationship between age of patents and MP content (cell membrane glycoproteins, phosphatidylserine or miRNA profile) is possible. MPs will be obtained from T1DM (n = 30) T2DM (n = 30), MS (n = 30) and controls (n = 30). Retinopathy in diabetic patients will be assessed by imaging method. Biological profile of MPs will be assessed in vitro by means of flow cytometry, molecular biology methods and cell proliferation assays.

scholarly journals Elevated Levels of Plasma IgA Autoantibodies against Oxidized LDL Found in Proliferative Diabetic Retinopathy but Not in Nonproliferative Retinopathy

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Satu Vavuli ◽  
Tuire Salonurmi ◽  
Sirpa Loukovaara ◽  
Antti E. Nissinen ◽  
Markku J. Savolainen ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Oxidized Ldl ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 1 Diabetic Patients ◽  
Type 2 Diabetic

Aims. This study investigated the association of autoantibodies binding to oxidized low-density lipoproteins (oxLDL) in diabetic retinopathy (DR). Methods. Plasma from 229 types 1 and 2 patients with DR including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) was analysed with ELISA-based assay to determine IgA, IgG, and IgM autoantibody levels binding to oxLDL. The controls were 106 diabetic patients without retinopathy (NoDR) and 139 nondiabetic controls (C). Results. PDR group had significantly higher IgA autoantibody levels than DME or NoDR: mean 94.9 (SD 54.7) for PDR, 75.5 (41.8) for DME (p=0.001), and 76.1 (48.2) for NoDR (p=0.008). There were no differences in IgG, IgM, or IgA that would be specific for DR or for DME. Type 2 diabetic patients had higher levels of IgA autoantibodies than type 1 diabetic patients (86.0 and 65.5, resp., p=0.004) and the highest levels in IgA were found in type 2 diabetic patients with PDR (119.1, p>0.001). Conclusions. IgA autoantibodies were increased in PDR, especially in type 2 diabetes. The high levels of IgA in PDR, and especially in type 2 PDR patients, reflect the inflammatory process and enlighten the role of oxLDL and its autoantibodies in PDR.

scholarly journals Diabetic Retinopathy and Central Corneal Thickness

2019 ◽  
Vol 3 (3) ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Central Corneal Thickness ◽  
Corneal Thickness ◽  
Diabetic Patients ◽  
Type I ◽  
Type Ii ◽  
The Mean

Background: Diabetes mellitus (DM) is a metabolic disease that can lead to many ocular complications such as increased Central Corneal Thickness (CCT), cataracts, and diabetic retinopathy. The aim of this study was to compare the CCT between subjects with type I and type II diabetes. Method: This was a retrospective study which included subjects with diabetes (with and without Diabetic Retinopathy (DR)) aged between 18 to 80 years old. The data collected were type and duration of diabetes mellitus, diabetes treatment, glycated hemoglobin level, visual acuity, CCT, and intra ocular pressure. Subjects were divided into subgroup (with and without DR). Statistical program (SPSS) was used to compare the central corneal thickness between the groups. Result: A total of 205 subjects with type I (n=100) and type II (n=105) diabetes were included in this study. In type 1 DM, the mean CCT was 547.06±27.3 microns in patients with diabetic retinopathy (DR) and 533.85±26.8 microns in patients without DR. In type 2 DM, the mean CCT was 542.85±39.3 microns in patients with DR and 532.44±27.4 microns in patients without DR. The CCT in type 1 diabetic patients was higher in both groups (with and without DR) than the CCT in type 2 diabetic patients in both groups (with and without DR). However, this was not statistically significant. Conclusion: The type of diabetes mellitus did not affect CCT. The presence of diabetic retinopathy in either type I or type II diabetes mellitus can affect the measurements of CCT.

scholarly journals Inflammation and neuropeptides: the connection in diabetic wound healing

2009 ◽  
Vol 11 ◽  
Author(s):  
Leena Pradhan ◽  
Christoph Nabzdyk ◽  
Nicholas D. Andersen ◽  
Frank W. LoGerfo ◽  
Aristidis Veves
Keyword(s):  
Wound Healing ◽  
Wound Repair ◽  
Major Complication ◽  
Limb Amputation ◽  
Diabetic Patients ◽  
Diabetic Wound ◽  
Molecular Events ◽  
Diabetic Wound Healing

Abnormal wound healing is a major complication of both type 1 and type 2 diabetes, with nonhealing foot ulcerations leading in the worst cases to lower-limb amputation. Wound healing requires the integration of complex cellular and molecular events in successive phases of inflammation, cell proliferation, cell migration, angiogenesis and re-epithelialisation. A link between wound healing and the nervous system is clinically apparent as peripheral neuropathy is reported in 30–50% of diabetic patients and is the most common and sensitive predictor of foot ulceration. Indeed, a bidirectional connection between the nervous and the immune systems and its role in wound repair has emerged as one of the focal features of the wound-healing dogma. This review provides a broad overview of the mediators of this connection, which include neuropeptides and cytokines released from nerve fibres, immune cells and cutaneous cells. In-depth understanding of the signalling pathways in the neuroimmune axis in diabetic wound healing is vital to the development of successful wound-healing therapies.

Polymorphisms of the Plasminogen Activator Inhibitor- 1 Gene in Type 1 and Type 2 Diabetes, and in Patients with Diabetic Retinopathy

1994 ◽  
Vol 71 (06) ◽  
pp. 731-736 ◽  
Author(s):  
M W Mansfield ◽  
M H Stickland ◽  
A M Carter ◽  
P J Grant
Keyword(s):  
Diabetic Retinopathy ◽  
Plasminogen Activator Inhibitor ◽  
Allelic Frequency ◽  
Repeat Sequence ◽  
Dinucleotide Repeat ◽  
Plasminogen Activator Inhibitor 1 ◽  
The Difference ◽  
Pai 1

SummaryTo identify whether genotype contributes to the difference in PAI-1 levels in type 1 and type 2 diabetic subjects and whether genotype relates to the development of retinopathy, a Hind III restriction fragment length polymorphism and two dinucleotide repeat polymorphisms were studied. In 519 Caucasian diabetic subjects (192 type 1, 327 type 2) and 123 Caucasian control subjects there were no differences in the frequency of the Hind III restriction alleles (type 1 vs type 2 vs control: allele 1 0.397 vs 0.420 vs 0.448; allele 2 0.603 vs 0.580 vs 0.552) nor in the allelic frequency at either dinucleotide repeat sequence. In 86 subjects with no retinopathy at 15 years or more from diagnosis of diabetes and 190 subjects with diabetic retinopathy there was no difference in the frequency of Hind III restriction alleles (retinopathy present vs retinopathy absent: allele 1 0.400 vs 0.467; allele 2 0.600 vs 0.533) nor in the allelic frequencies at either dinucleotide repeat sequence. The results indicate that there is no or minimal influence of the PAI-1 gene on either PAI-1 levels or the development of diabetic retinopathy in patients with diabetes mellitus.

Male Type 2 Diabetic Patients Have Higher Diabetic Retinopathy Prevalence

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 599-P ◽  
Author(s):  
SARA CHERCHI ◽  
ALFONSO GIGANTE ◽  
PIERPAOLO CONTINI ◽  
DANILA PISTIS ◽  
ROSANGELA M. PILOSU ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Male Type ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document